A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Richard F. Riedel, Karla V. Ballman, Yao Lu, Steven Attia, Elizabeth Trice Loggers, Kristen N. Ganjoo, Michael B. Livingston, Warren Allen Chow, Jennifer A. Wright, John Harris Ward, Daniel A. Rushing, Scott H. Okuno, Damon R. Reed, David A. Liebner, Vicki Leigh Keedy, Leo Mascarenhas, Lara Emily Davis, Christopher W. Ryan, Denise K. Reinke, Robert G. Maki
Institutions: Duke Medical Center, Weill Cornell Medicine, NewYork–Presbyterian Hospital, Mayo Clinic in Florida, Seattle Cancer Care Alliance, Stanford Cancer Institute, Levine Cancer Institute, City Of Hope National Medical Center, City of Hope, University of Utah, Huntsman Cancer Institute, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Mayo Clinic, Moffitt Cancer Center, The Ohio State University, Vanderbilt University Medical Center, University of Southern California, Children's Hospital Los Angeles, Oregon Health & Science University, OHSU Knight Cancer Institute, Sarcoma Alliance for Research through Collaboration, Northwell Health, Cold Spring Harbor Laboratory
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891705564